—REVLIMID Recognized for 'Special Therapeutic Development'—
North Hollywood, CA - September 25, 2008 - The International Myeloma Foundation (IMF) today noted REVLIMID® was granted the Prix Galien USA 2008 Award for Special Therapeutic Development, and congratulated Celgene and all of the researchers, patients and physicians who helped in the drug's development. REVLIMID is an oral cancer drug for the treatment of multiple myeloma. The Prix Galien Award, considered to be the highest accolade for pharmaceutical research and development, was presented during a ceremony in New York City on September 24.
Susie Novis, president and co-founder of the IMF said, "REVLIMID, along with the other novel therapies, signals an era where incurable cancers will be transformed into chronic, manageable diseases. Myeloma patients are well aware of the contributions this drug has made to improving outcomes, and we are pleased that the esteemed Prix Galien awards committee has recognized that same value."
The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines. Prix Galien is considered by many to be the pharmaceutical industry's equivalent of the Nobel Prize. The recognition of REVLIMID was one of 6 pharmaceutical awards presented by Prix Galien this year and is the only one in the field of multiple myeloma.
David Girard, IMF Executive Director, added, "As the award criteria state, REVLIMID is a prime example of 'pharmaceutical science that improves the human condition,' and offers life-changing benefits to myeloma patients and the medical community."
Multiple myeloma is a cancer of the bone marrow that affects production of blood cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.
Prix Galien was first established in 1970 by French pharmacist Roland Mehl and was inaugurated in the United States in September 2007. The Prix Galien USA awards committee comprises 11 individuals including Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals.
ABOUT THE INTERNATIONAL MYELOMA FOUNDATION
The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 185,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses in four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 200 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank on a Cure®, a unique gene bank to advance myeloma research. The IMF was rated as the number one resource for patients in an independent survey by the Target Research Group. The IMF can be reached at (800) 452-CURE, or out of the United States at +1-818-487-7455. More information is available at www.myeloma.org.
Media Contact: Stephen Gendel or Jennifer Anderson +1-212-918-4650